Anti-IGSF9B monoclonal antibody

Pre-made anti-IGSF9B monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to IGSF9B/IGSF9B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1006-Ab-1/ GM-Tg-hg-IP1006-Ab-2Anti-Human IGSF9B monoclonal antibodyHuman
GM-Tg-rg-IP1006-Ab-1/ GM-Tg-rg-IP1006-Ab-2Anti-Rat IGSF9B monoclonal antibodyRat
GM-Tg-mg-IP1006-Ab-1/ GM-Tg-mg-IP1006-Ab-2Anti-Mouse IGSF9B monoclonal antibodyMouse
GM-Tg-cynog-IP1006-Ab-1/ GM-Tg-cynog-IP1006-Ab-2Anti-Cynomolgus/ Rhesus macaque IGSF9B monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1006-Ab-1/ GM-Tg-felg-IP1006-Ab-2Anti-Feline IGSF9B monoclonal antibodyFeline
GM-Tg-cang-IP1006-Ab-1/ GM-Tg-cang-IP1006-Ab-2Anti-Canine IGSF9B monoclonal antibodyCanine
GM-Tg-bovg-IP1006-Ab-1/ GM-Tg-bovg-IP1006-Ab-2Anti-Bovine IGSF9B monoclonal antibodyBovine
GM-Tg-equg-IP1006-Ab-1/ GM-Tg-equg-IP1006-Ab-2Anti-Equine IGSF9B monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1006-Ab-1/ GM-Tg-hg-IP1006-Ab-2; GM-Tg-rg-IP1006-Ab-1/ GM-Tg-rg-IP1006-Ab-2;
GM-Tg-mg-IP1006-Ab-1/ GM-Tg-mg-IP1006-Ab-2; GM-Tg-cynog-IP1006-Ab-1/ GM-Tg-cynog-IP1006-Ab-2;
GM-Tg-felg-IP1006-Ab-1/ GM-Tg-felg-IP1006-Ab-2; GM-Tg-cang-IP1006-Ab-1/ GM-Tg-cang-IP1006-Ab-2;
GM-Tg-bovg-IP1006-Ab-1/ GM-Tg-bovg-IP1006-Ab-2; GM-Tg-equg-IP1006-Ab-1/ GM-Tg-equg-IP1006-Ab-2
Products NameAnti-IGSF9B monoclonal antibody
Formatmab
Target NameIGSF9B
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-IGSF9B monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1006-Ag-1Recombinant multi-species TUTLB/ IGSF9B protein


    Target information

    Target IDGM-IP1006
    Target NameIGSF9B
    Gene ID22997,235086,315510,699412,489272,101095043,517432,100072847
    Gene Symbol and SynonymsAI854107,Gm508,IGSF9B,LINC00947,MIR4697HG,mKIAA1030,RGD1564717
    Uniprot AccessionQ9UPX0,D3ZB51
    Uniprot Entry NameTUTLB_HUMAN,TUTLB_RAT
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000080854
    Target ClassificationN/A

    The target: IGSF9B, gene name: IGSF9B, also named as . Predicted to enable kinase binding activity. Predicted to be involved in synaptic membrane adhesion. Predicted to act upstream of or within homophilic cell adhesion via plasma membrane adhesion molecules and positive regulation of inhibitory postsynaptic potential. Predicted to be located in dendrite; inhibitory synapse; and neuronal cell body. Predicted to be active in GABA-ergic synapse; neuron projection; and postsynaptic specialization of symmetric synapse. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.